| |
Wednesday, April 2, 2025 | 11:00 AM ET
Get expert strategies for validating robust, scalable immunogenicity assays to reduce costs and minimize rework from early trials to market.
Register now. +(002)+140w+(3).png)
|
|
Today’s Big NewsMar 31, 2025 |
|
Tuesday, April 8, 2025 | 1pm ET / 10am PT Learn how AI-powered digital phenotyping and real-world data (RWD) help identify overlooked patient populations, bridge gaps between clinical guidelines and real-world treatment, and refine commercial strategies. Join experts to discover how AI-driven insights can optimize market positioning and ensure therapies reach the right patients. Register now! 
|
|
| By Darren Incorvaia While coming back down from 2023’s dizzying high, Merck & Co. still managed to hang on to the top spot of our annual research and development budgets list. |
|
|
|
By Fraiser Kansteiner In resigning as director of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D., blast the promotion of vaccine disinformation under new HHS secretary Robert F. Kennedy Jr. |
By Darren Incorvaia AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its programs spanning multiple therapeutic areas. |
By Gabrielle Masson Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone. |
|
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
By Nick Paul Taylor Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over rivals from Amgen and Novartis. |
By James Waldron Vertex is ending work on one of its two islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. |
By Darren Incorvaia Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests certain approved drugs could possibly be repurposed for a severe fatigue condition that currently has no approved treatment, while also highlighting prospective targets for new therapeutics. A week later, the NIH terminated grant funding to Columbia's center studying the condition. |
By Nick Paul Taylor Transcend Therapeutics has glided over the bar for success, linking its MDMA analog to improvements in PTSD symptoms that began on Day 8 and persisted through Day 64 of its phase 2 trial. |
By James Waldron Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to can the entire wet age-related macular degeneration program. |
By James Waldron BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal has been shown to reduce uclers in a phase 2 study of patients with a diabetic foot infection. |
By Angus Liu A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio, and the company's board is "carefully reviewing" the offer, which values the biotech 50% higher than the original deal. |
By Kevin Dunleavy Merck revealed data from a phase 3 study of pulmonary arterial hypertension drug Winrevair, which showed it reduced the risk of all-cause death, lung transplantation and hospitalization by 76% versus placebo, despite maximal background therapy. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 11am ET / 8am PT Copay programs are designed to make treatments more affordable, but too often, patients don’t know they exist or how to use them. That means financial assistance goes unused, medications go unfilled, and patients face unnecessary barriers to starting and staying on treatment. Join us to learn how to move beyond outdated, manual copay distribution methods. Register now. |
|
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
